CLINICAL_TRIALS
trial_result
· 2024-09-19
Clinical Trial Update: Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Summary
Pfizer's completed trial evaluates post-alectinib treatment patterns in ALK-positive non-small cell lung cancer. The study results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Pfizer | Conditions: Non-Small-Cell Lung Carcinoma | Status: COMPLETED | Results posted: 2024-09-19